Loading...

Kwong, Louis M

Title(s)Professor of Clinical _____, Orthopaedic Surgery
Phone(310) 222-2716
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Shymon SJ, Arthur D, Keeling P, Rashidi S, Kwong LM, Andrawis JP. Current illicit drug use profile of orthopaedic trauma patients and its effect on hospital length of stay. Injury. 2020 Feb 17. PMID: 32145902.
      View in: PubMed
    2. Kwong LM, Turpie AGG, Tamayo S, Peacock WF, Yuan Z, Sicignano N, Hopf KP, Patel MR. A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban. Curr Med Res Opin. 2017 09; 33(9):1717-1723. PMID: 28678604.
      View in: PubMed
    3. Kwong LM, Kimball JA. Postorthopedic Surgery Joint Replacement Surgery Venous Thromboembolism Prophylaxis. Hematol Oncol Clin North Am. 2016 10; 30(5):1007-18. PMID: 27637304.
      View in: PubMed
    4. Kwong L, Turpie AG. Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients. Curr Orthop Pract. 2015 May; 26(3):299-305. PMID: 25973138.
      View in: PubMed
    5. Kwong LM. Comparative safety and efficacy of antithrombotics in the management of venous thromboembolism after knee or hip replacement surgery: focus on rivaroxaban. Clin Pharmacol. 2013; 5:143-8. PMID: 23946671.
      View in: PubMed
    6. Kwong LM. Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis. Orthopedics. 2012 Nov; 35(11):919; discussion 919. PMID: 23127435.
      View in: PubMed
    7. Kwong LM, Tong LM. Drug interactions with rivaroxaban following total joint replacement surgery. Ann Pharmacother. 2012 Sep; 46(9):1232-8. PMID: 22932305.
      View in: PubMed
    8. Kwong LM. Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis. Orthopedics. 2012 Jun; 35(6):e932-8;discussion e939. PMID: 22691670.
      View in: PubMed
    9. Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective. Pharmacoeconomics. 2012 Feb 01; 30(2):87-101. PMID: 22187932.
      View in: PubMed
    10. Kwong LM, Kistler KD, Mills R, Wildgoose P, Klaskala W. Thromboprophylaxis, bleeding and post-operative prosthetic joint infection in total hip and knee arthroplasty: a comprehensive literature review. Expert Opin Pharmacother. 2012 Feb; 13(3):333-44. PMID: 22220855.
      View in: PubMed
    11. Anderson FA, Huang W, Friedman RJ, Kwong LM, Lieberman JR, Pellegrini VD. Prevention of venous thromboembolism after hip or knee arthroplasty: findings from a 2008 survey of US orthopedic surgeons. J Arthroplasty. 2012 May; 27(5):659-66.e5. PMID: 22035977.
      View in: PubMed
    12. Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective. J Med Econ. 2011; 14(6):824-34. PMID: 22023098.
      View in: PubMed
    13. Kwong LM. Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data. Vasc Health Risk Manag. 2011; 7:461-6. PMID: 21822393.
      View in: PubMed
    14. Kwong LM. Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty. Am J Manag Care. 2011 Feb; 17(1 Suppl):S22-6. PMID: 21517652.
      View in: PubMed
    15. Baser O, Supina D, Sengupta N, Wang L, Kwong L. Clinical and cost outcomes of venous thromboembolism in Medicare patients undergoing total hip replacement or total knee replacement surgery. Curr Med Res Opin. 2011 Feb; 27(2):423-9. PMID: 21192759.
      View in: PubMed
    16. Kwong LM. Never events and related quality measures following total hip and total knee replacement. Orthopedics. 2010 Nov; 33(11):838. PMID: 21155137.
      View in: PubMed
    17. Wells PS, Borah BJ, Sengupta N, Supina D, McDonald HP, Kwong LM. Analysis of venous thromboprophylaxis duration and outcomes in orthopedic patients. Am J Manag Care. 2010 Nov; 16(11):857-63. PMID: 21348557.
      View in: PubMed
    18. Baser O, Supina D, Sengupta N, Wang L, Kwong L. Impact of postoperative venous thromboembolism on Medicare recipients undergoing total hip replacement or total knee replacement surgery. Am J Health Syst Pharm. 2010 Sep 01; 67(17):1438-45. PMID: 20720243.
      View in: PubMed
    19. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009 May 16; 373(9676):1673-80. PMID: 19411100.
      View in: PubMed
    20. Kwong LM, Happe LE, Horblyuk R, Farrelly E. Decreased venous thromboembolism with injectable vs oral anticoagulation after discharge for major orthopedic surgery. J Arthroplasty. 2008 Sep; 23(6 Suppl 1):25-30. PMID: 18722300.
      View in: PubMed
    21. Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, Gent M, Haas S, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AG. Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery. Clin Pharmacokinet. 2008; 47(3):203-16. PMID: 18307374.
      View in: PubMed
    22. Fisher WD, Eriksson BI, Bauer KA, Borris L, Dahl OE, Gent M, Haas S, Homering M, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AG. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost. 2007 Jun; 97(6):931-7. PMID: 17549294.
      View in: PubMed
    23. Shorr AF, Kwong LM, Sarnes M, Happe L, Farrelly E, Mody-Patel N. Venous thromboembolism after orthopedic surgery: implications of the choice for prophylaxis. Thromb Res. 2007; 121(1):17-24. PMID: 17449088.
      View in: PubMed
    24. Sullivan SD, Kwong L, Nutescu E. Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery. Value Health. 2006 Mar-Apr; 9(2):68-76. PMID: 16626410.
      View in: PubMed
    25. Kwong LM. Deep vein thrombosis prophylaxis: better living through chemistry--in the affirmative. J Arthroplasty. 2005 Jun; 20(4 Suppl 2):12-4. PMID: 15991121.
      View in: PubMed
    26. Kwong LM. Hip fracture and venous thromboembolism in the elderly. J Surg Orthop Adv. 2004; 13(3):139-48. PMID: 15559689.
      View in: PubMed
    27. Kwong LM. Balancing new technology with established techniques. Orthopedics. 2003 Aug; 26(8 Suppl):s873-4. PMID: 12934743.
      View in: PubMed
    28. Kwong LM, Miller AJ, Lubinus P. A modular distal fixation option for proximal bone loss in revision total hip arthroplasty: a 2- to 6-year follow-up study. J Arthroplasty. 2003 Apr; 18(3 Suppl 1):94-7. PMID: 12730939.
      View in: PubMed
    29. Kwong LM. Selective factor Xa inhibitors: practical guidelines for use. Am J Orthop (Belle Mead NJ). 2002 Nov; 31(11 Suppl):3. PMID: 12463576.
      View in: PubMed
    30. Kwong LM, Muntz JE. Thromboprophylaxis dosing: the relationship between timing of first administration, efficacy, and safety. Am J Orthop (Belle Mead NJ). 2002 Nov; 31(11 Suppl):16-20. PMID: 12463579.
      View in: PubMed